6MO: Safety and clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC)

Salman R. Punekar, Dehan Hong, Jia Luo, S-H.I. Ou, M.L. Johnson, A.I. Spira, Ignacio Garrido‐Laguna, J.W. Goldman, Benjamin Herzberg, Andreas Saltos, Priyam Mitra, Aparna Hegde, Rashmi Vora, Minoti Hiremath, Kathryn C. Arbour